News
EQS-News: Evotec SE: Invitation to Conference Call
EQS-News: Evotec SE: Invitation to Conference Call
Why Alibaba Stock Was Falling Again Today
Shares of Alibaba Group (NYSE: BABA) were sliding again today as further signs of weakness emerged in the Chinese economy.
In an effort to restore optimism about China's recovery, the country
Why Amarin Stock Skyrocketed Today
Shares of Amarin (NASDAQ: AMRN) skyrocketed 32.9% on Wednesday after the biopharmaceutical company announced strong preliminary fiscal fourth-quarter results, a new share-repurchase authorization
EQS-News: Evotec and Crohn´s & Colitis Foundation enter agreement to advance drug discovery for novel IBD therapies
EQS-News: Evotec and Crohn´s & Colitis Foundation enter agreement to advance drug discovery for novel IBD therapies
EQS-News: MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference
EQS-News: MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference
EQS-News: Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb
EQS-News: Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb
EQS-Adhoc: QIAGEN N.V.: QIAGEN to return approximately $300 million to shareholders through a synthetic share repurchase
EQS-Adhoc: QIAGEN N.V.: QIAGEN to return approximately $300 million to shareholders through a synthetic share repurchase
EQS-News: Gerresheimer AG: Gerresheimer and Aptar Digital Health collaborate to develop integrated solution for cancer therapy
EQS-News: Gerresheimer AG: Gerresheimer and Aptar Digital Health collaborate to develop integrated solution for cancer therapy
EQS-News: Evotec and Owkin enter an A.I.-powered strategic partnership to accelerate therapeutics pipeline in oncology and I&I
EQS-News: Evotec and Owkin enter an A.I.-powered strategic partnership to accelerate therapeutics pipeline in oncology and I&I
Almirall Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases
Almirall S.A. (BME: ALM), a global pharmaceutical company focused on medical dermatology, today announced the initiation of the phase I study evaluating the safety, pharmacokinetics,
EQS-News: Evotec receives US$ 2.5 m grant to leverage human iPSC-derived teratogenicity platform for global health programmes
EQS-News: Evotec receives US$ 2.5 m grant to leverage human iPSC-derived teratogenicity platform for global health programmes
Coachella Valley Behavioral Health Hosts Ceremony to Celebrate Grand Opening
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced the opening of its newest acute care hospital, Coachella Valley Behavioral Health, located at 81555 JFK Court in Indio, California. A
EQS-News: Evotec enters partnership with Charité to expand molecular patient database in autoimmune diseases
EQS-News: Evotec enters partnership with Charité to expand molecular patient database in autoimmune diseases
EQS-News: MorphoSys Places New Shares from Cash Capital Increase with Gross Proceeds of Approximately EUR 102.7 Million
EQS-News: MorphoSys Places New Shares from Cash Capital Increase with Gross Proceeds of Approximately EUR 102.7 Million
EQS-Adhoc: Ad hoc: MorphoSys AG Places New Shares From Cash Capital Increase with Gross Proceeds Of Approximately EUR 102.7 million
EQS-Adhoc: Ad hoc: MorphoSys AG Places New Shares From Cash Capital Increase with Gross Proceeds Of Approximately EUR 102.7 million
EQS-Adhoc: Ad hoc: MorphoSys AG Launches Cash Capital Increase by way of Accelerated Bookbuilding Process
EQS-Adhoc: Ad hoc: MorphoSys AG Launches Cash Capital Increase by way of Accelerated Bookbuilding Process
EQS-News: MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
EQS-News: MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
EQS-News: Evotec-partner Jingxin receives approval for EVT201 in China
EQS-News: Evotec-partner Jingxin receives approval for EVT201 in China
EQS-News: Gerresheimer AG: Guido Pickert to head up Investor Relations at Gerresheimer
EQS-News: Gerresheimer AG: Guido Pickert to head up Investor Relations at Gerresheimer
EQS-News: Gerresheimer: Green electricity from wind for German production sites
EQS-News: Gerresheimer: Green electricity from wind for German production sites
EQS-News: MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
EQS-News: MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
EQS-Adhoc: Ad hoc: MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
EQS-Adhoc: Ad hoc: MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results
EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results